Posts with tag: monuments
Pfizer's Q4 2024 earnings beat expectations, with revenue up 7% YoY to $63.6B and EPS of $3.12 exceeding estimates. The company is downsizing to offset waning COVID-19 product revenue, targeting $4.5B in savings by 2025. Despite headwinds such as patent expirations and Medicare price negotiations, Pfizer aims to enhance shareholder value through R&D productivity and strategic priorities.
Published on: February 04, 2025, 05:03 PM UTC